Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Osteoporosis therapy receives positive opinion in Europe
July 28th, 2005
Roche and GlaxoSmithKline (GSK) announced that Bonviva (ibandronic acid), the first and only once-monthly tablet for the effective treatment of postmenopausal osteoporosis, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP). With once-monthly Bonviva, a potent and highly effective bisphosphonate, patients will only have to take 12 tablets a year versus 52 required with current weekly bisphosphonate treatments. This is particularly important as almost two-thirds of patients stop taking their osteoporosis treatment within a year, foregoing the bone building benefits these drugs can provide over time. Data...
Source: Women's Health Weekly (2005-07-28)
|
